期刊
IMMUNOTHERAPY
卷 12, 期 18, 页码 1325-1340出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0215
关键词
fostamatinib; immune thrombocytopenia; ITP; spleen tyrosine kinase; targeted therapy; tyrosine kinase inhibitor
类别
资金
- Amgen
- Argenx
- Grifols
- GSK
- Novartis
- Roche
- BMS
- Octapharma
- Baxter
- Grifols S.A. (Barcelona, Spain)
Management of chronic immune thrombocytopenia (ITP) is going through a transition, with the main driving forces being a better understanding of the disease, recognition that platelet count is less important than bleeding symptoms, and the availability of new therapies. The heterogeneity of chronic ITP makes treatment challenging, and highlights the need for a personalized approach. A key aspect of tailored treatment is the availability of agents to target specific underlying pathophysiological mechanisms. In this review, we examine the evidence for orally bioavailable fostamatinib and its active moiety, tamatinib (R406), which has been approved for the treatment of chronic adult ITP. Fostamatinib inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis and, as such, represents an active therapy targeting a previously unexplored mechanism of ITP pathogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据